Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Clinical Activity of RET Tyrosine Kinase Inhibitor (TKI) plus Chemotherapy after Progression on a RET TKI in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report – JTO Clinical and Research Reports”
Title: Clinical Activity of RET Tyrosine Kinase Inhibitor (TKI) plus Chemotherapy after Progression on a RET TKI in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report
Authors: Alvaro Guimaraes Paula, Ximeng Liu, Amirali Karimi, Kyle Concannon, Simon Heeke, Yasir Y. Elamin, Kaiwen Wang, Jenny V. Pozadzides, Natalie Vokes, Janet Tu, Anne Tsao, Marcelo V. Negrao, Jianjun Zhang, Eric K. Singhi, Bingman Zhang, Waree Rinsurongkawon, Isadora Guimaraes Martins, Hai Tran, Don L. Gibbons, Monique B. Nilsson, John V. Heymach
Other articles featuring Vivek Subbiah on OncoDaily.